BHP Attracts AI-Focused Investors as Copper Demand Surges 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
SAN DIEGO, May 02, 2018 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that it will report its first quarter 2018 financial and operating results after the close of U.S. financial markets on Wednesday, May 9, 2018. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | May 9, 2018 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 3189378 |
| Via web: | www.traconpharma.com; “Events and Presentations” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
| Company Contact: Patricia Bitar Chief Financial Officer (858) 550-0780 ext. 223 [email protected] | Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected] | |
